// R&D pipeline

Oncolytic mRNA

eTheRNA is developing mRNA-based products mimicking the action of oncolytic viruses. A mRNA-based approach has several advantages over oncolytic viruses:

  • It's easier to regulate the mode of action of an mRNA-based product
  • Side effects are expected to be less severe
  • No viral antigens or anti-vector immunity

A single construct or a mix of naked or packaged mRNA is delivered directly into the  tumor site giving direct access to the effector site of the therapy. This modality offers opportunities to develop products with cell-lytic, tumor microenvironment modifying and immune stimulating properties.

Preliminary in vitro and ex vivo experiments  have provided impressive anti-tumor responses in both the treated and untreated tumors suggesting a systemic response from a loco-regional delivery.

Galileilaan 19, 2845 Niel, Belgium

Our Address

Our Mailbox

+32 3 369 17 40

Our Phone

© 2020 Etherna | Studio Hanswijk